News & Updates
Showing Multidisciplinary articles
Showing
Show Multimedia Only

Progressive phenotype predicts transplantation-free survival in ILD, IPF patients
02 May 2022
Nearly one in four nonidiopathic pulmonary fibrosis (non-IPF) patients with a fibrosing form of interstitial lung disease (FILD) develop a progressive phenotype relative to almost 60 percent of IPF patients, reveals a study. Survival of non-IPF FILD patients with such phenotype is similar to IPF.
02 May 2022

Brigatinib a potential standard treatment alternative for treatment-naive ALK+ NSCLC
30 Apr 2022
byAudrey Abella
In patients with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer (ALK+ NSCLC) who were ALK inhibitor-naïve, brigatinib showed superior efficacy and safety over crizotinib, according to the final results of the phase III ALTA-1L* trial presented at ELCC 2022.
30 Apr 2022






